Abstract:Abstract Small cell lung carcinoma (SCLC) is prototypical of cancers with exceptional chemoresistance, and metastatic capabilities fueled by remarkable heterogeneity. The cell-extrinsic factors that govern SCLC heterogeneity are poorly understood especially since non-genetic mechanisms are thought to be major contributors to its intratumoral heterogeneity and plasticity. In order to answer the above question, we sought to inquire about the role of tumor microenvironment (TME) in SCLC heterogeneity which is challenged universally by a lack of patient-derived adequate tumor biopsies. Leveraging large tumor sampling performed at rapid autopsies done on 10 different patients who died from SCLC metastatic disease, we developed a multi-omics approach involving spatial transcriptomics (ST) (Whole transcriptomic atlas), bulk whole genome sequencing, and multiplex immunofluorescence (IF) and standard immunohistochemistry (IHC) to better characterize spatially proximate tumor (36 segments), TME (32 segments) and 4 normal segments. Genomically, SCLC characteristic alterations like TP53 (70%) and RB1 (80%) inactivation and MYC (50%)/MYCL (80%) were evident. ST profiling reveals three distinct tumor subtypes corresponding to the known high-Neuroendocrine (NE) and low-NE SCLC subtypes as well as a novel hybrid-NE state with multiple elevated cancer hallmark capabilities and morphological evidence of nesting and budding. High-NE and hybrid-NE subtypes appear to be driven by ASCL1 and the low-NE subtype resembles the SCLC- inflamed subtype. ST profiling of proximate TMEs reveals similar heterogeneity that is closely linked with SCLC-NE heterogeneity at inter-patient and intra-tumoral levels with distinct features and cellular compositions. Specifically, low-NE TME is marked by increased pro and anti-tumor features including B cells, NK cells, M1-macrophages, and evidence of more checkpoint molecules. High-NE TMEs are predominated by a distinct absence of adaptive immune cells and a strong presence of M2 macrophages. Most strikingly the hybrid-NE TME shows a significant enrichment of immunosuppressive cancer-associated fibroblasts with the absence of T and other adaptive immune cells confirmed using IHC and IF. Next, we attempt to narrow down the fibroblast growth factor receptor (FGF) axis as one of the unique TME-driven factor(s) that could groom non-NE features in SCLC fueling their plasticity and heterogeneity. Subsequently using various SCLC cell lines, we demonstrate that in-vitro modulation of FGFR in SCLC may constrain their plasticity by downregulation of NOTCH signaling, MYC, and its downstream effector REST. We describe the remarkable phenotypic heterogeneity of SCLC tumor and TME and demonstrate their interlinking as well as potential translational avenues of leveraging the cellular crosstalk in order to constrain SCLC heterogeneity. Citation Format: Parth Anil Desai, Nobuyuki Takahashi, Yingying Cao, Christopher Schultz, Darryl Nousome, Desiree Tillo, Lakshya Chauhan, Mayank tandon, Rajesh kumar Bhardwaj, Delphine Lissa, Vinodh Rajapakse, Suresh kumar, Yang Zhang, Elmeskini Rajaa, Donna Butcher, Linda Scuito, Jingjing Gong, Brett Schroder, Andrew Warner, Samantha Nichols, Jordan Kimberly, Alejandro Schaffer, Mohit kumar Jolly, Stephen Hewitt, Anish Thomas. Distinct immunosuppressive tumor microenvironment modulates small cell lung carcinoma neuroendocrine phenotypic plasticity and heterogeneity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5828.

Cold and Heterogeneous T Cell Repertoire is Associated with Copy Number Aberrations and Loss of Immune Genes in Small-Cell Lung Cancer.

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and Its Impact on Survival

Distinct Patterns of Somatic Genomic Alterations and Mutational Signatures in Central and Peripheral-Type Small-Cell Lung Cancer

Multi-region Exome Sequencing Reveals the Intratumoral Heterogeneity of Surgically Resected Small Cell Lung Cancer

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Association of the T-cell Receptor Landscape with Survival in Non-Small Cell Lung Cancer.

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-Small Cell Lung Cancer at Single Cell Resolution

Abstract 2822: Heterogeneity of CD56+ circulating tumor cells and derived xenografts and response to treatment in small cell lung cancer

Intratumoral Heterogeneity and Tumor Evolution of Small Cell Lung Cancer Through Multi-Regional Sequencing.

Peripheral T-cell receptor repertoire dynamics in small cell lung cancer

Abstract 7567: In-depth mass cytometry analysis reveals different immune cell composition of unique molecular subtypes in extensive stage small-cell lung cancer

MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer

Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities.

Abstract 213: Exome Sequencing of Paired Primary and Relapsed Small Cell Lung Cancers Reveals Increased Copy Number Aberration Complexity to Be Associated with Disease Relapse

Abstract 5828: Distinct immunosuppressive tumor microenvironment modulates small cell lung carcinoma neuroendocrine phenotypic plasticity and heterogeneity

Abstract A005: Transcriptional profiling of tumor heterogeneity and chemoresistance in small cell lung cancer

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

Abstract A017: Identifying proliferative and immune-modulatory drivers of small cell lung cancer (SCLC)